CLSD — Clearside Biomedical Balance Sheet
0.000.00%
Last trade - 00:00
- $93.40m
- $64.48m
- $8.23m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 22.6 | 17.3 | 30.4 | 48.3 | 28.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 10 | 0 | 0.17 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 25.2 | 18.1 | 42.1 | 49.4 | 30.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.2 | 0.944 | 0.607 | 1.87 | 3.87 |
Other Long Term Assets | |||||
Total Assets | 26.8 | 19.3 | 42.9 | 51.3 | 34 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10.9 | 9.94 | 4.64 | 5.78 | 6.81 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 15.6 | 10.6 | 4.93 | 40.7 | 49.9 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 11.2 | 8.76 | 38 | 10.6 | -15.9 |
Total Liabilities & Shareholders' Equity | 26.8 | 19.3 | 42.9 | 51.3 | 34 |
Total Common Shares Outstanding |